Literature DB >> 2988590

Enalapril (MK421) activation in man: importance of liver status.

I Larmour, B Jackson, R Cubela, C I Johnston.   

Abstract

The in vitro conversion of enalapril (MK421) to enalaprilic acid (MK422) in human autopsy tissues was examined. MK422 was measured by radioimmunoassay. Human cadaver liver was the only tissue in which significant conversion was demonstrated. The esterase activity was stable after post mortem. Autopsy liver tissues from patients with elevated ante mortem liver function tests were found to have a reduced rate of deesterification.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2988590      PMCID： PMC1463833          DOI： 10.1111/j.1365-2125.1985.tb02699.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  6 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Treatment of hypertension with angiotensin converting enzyme inhibitors.

Authors:  C I Johnston; B P McGrath; P G Matthews; B Jackson
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1982

3.  Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension.

Authors:  B Jackson; B P McGrath; C I Johnston
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1982

4.  Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.

Authors:  J Biollaz; J L Schelling; B Jacot Des Combes; D B Brunner; G Desponds; H R Brunner; E H Ulm; M Hichens; H J Gomez
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

Review 5.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

6.  Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations.

Authors:  L DiCarlo; K Chatterjee; W W Parmley; K Swedberg; B Atherton; D Curran; M Cucci
Journal:  J Am Coll Cardiol       Date:  1983-11       Impact factor: 24.094
  6 in total
  8 in total

1.  Absence of a pharmacokinetic interaction between enalapril and frusemide.

Authors:  A M Van Hecken; R Verbesselt; A Buntinx; V J Cirillo; P J De Schepper
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

Review 2.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

3.  Lisinopril pharmacokinetics in chronic renal failure.

Authors:  B Jackson; R B Cubela; E L Conway; C I Johnston
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

4.  The pharmacokinetics of enalapril in patients with compensated liver cirrhosis.

Authors:  T Baba; S Murabayashi; T Tomiyama; K Takebe
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 5.  Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview.

Authors:  R J MacFadyen; P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

Review 6.  Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.

Authors:  M Burnier; J Biollaz
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

7.  Pharmacokinetics of temocapril, an ACE inhibitor with preferential biliary excretion, in patients with impaired liver function.

Authors:  S Furuta; K Kiyosawa; M Higuchi; H Kasahara; H Saito; H Shioya; H Oguchi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  An improved synthesis of a fluorophosphonate-polyethylene glycol-biotin probe and its use against competitive substrates.

Authors:  Hao Xu; Hairat Sabit; Gordon L Amidon; H D Hollis Showalter
Journal:  Beilstein J Org Chem       Date:  2013-01-15       Impact factor: 2.883
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.